"Patrick Neven, MD, PhD Universitaire Ziekenhuizen Leuven, Belgium 5Live #ASCO20"
4:58
Key Insights on MONARCH 2: subgroup analysis of pts receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced BC
Key Insights on MONARCH 2: subgroup analysis of pts receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced BC